GlassScriptPhysician profile
Ana L Delgado
NPI 1124276886
$10,952.89
in general payments reported to CMS, 2019-2025
45 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $3,849 · 2021: $4,281 · 2022: $332 · 2023: $288 · 2024: $466 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $6,631.10 | 2019-2025 | Ongentys |
| Abbvie INC. | $597.70 | 2021-2025 | Qulipta, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $388.75 | 2019-2021 | |
| Ucb, INC. | $244.70 | 2020-2025 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $243.73 | 2019-2024 | |
| Biogen, INC. | $222.58 | 2019-2025 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $222.27 | 2019-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $195.97 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $168.25 | 2019-2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $159.55 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $148.39 | 2019-2020 | |
| Lundbeck LLC | $116.95 | 2019-2023 | Vyepti |
| Lilly USA, LLC | $115.50 | 2019-2020 | |
| Eisai INC. | $114.39 | 2020-2023 | |
| Adamas Pharmaceuticals, INC. | $108.09 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.